Orion is undervalued compared to peers, with high volatility presenting buying opportunities. Optimistic future earnings could boost cash flows and share value, but financial health is also crucial.
Gainers: •$Clovis Oncology (CLVS.US)$+40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial) •$Dare Bioscience (DARE.US)$+13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO) •$KULR Technology (KULR.US)$+9.5% (secured a battery sa...
Orion SA Stock Forum
• $Revlon (REV.US)$ +81% (Reliance mulling buyout of REV according to Economic Times)
• $United States Steel (X.US)$ +6.4% (issues upside EPS guidance),
• $Ellington Financial (EFC.US)$ +5% (reports book value per share)
• $Aurora Mobile (JG.US)$ +4.9% (receives RMB15 mln in special support funding from the Shenzhen Development and Reform Commission)
• $Citi Trends (CTRN.US)$ +4.4% (names new CFO)
• $Roku Inc (ROKU.US)$ +4.2% (ROKU an...
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...
No comment yet